Loading

logo

Journal of Clinical and Experimental Reproductive Medicine

ISSN: 3067-7904

Original Research Open Access

Autologous platelet-rich plasma to improve reproductive outcomes in women with diminished ovarian reserves: a prospective pilot study

Michelle Jia Min Loh1,*, Yiping Fan1,2,3,4, See Ling Loy1,2,3, Ker Yi Wong1, Chee Wai Ku1,2,3, Tat Xin Ee1, Tse Yeun Tan1, Veronique Viardot-Foucault1, Shuling Liu1, Sadhana Nadarajah1, Seong Feei Loh5, Jerry Kok Yen Chan1,2,3,4
  • 1Department of Reproductive Medicine, KK Women’s and Children’s Hospital, Singapore, Singapore
  • 2Obstetrics and Gynaecology Academic Clinical Program, Duke-NUS Medical School, Singapore, Singapore
  • 3SingHealth Duke-NUS Maternal and Child Health Research Institute, KK Women's and Children's Hospital, Singapore, Singapore
  • 4Experimental Fetal Medicine Group, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, Singapore, Singapore
  • 5Thomson Fertility Centre, Thomson Medical Centre, Singapore, Singapore
+ Affiliations - Affiliations

Corresponding Author

Michelle Jia Min Loh, Michelle.loh.j.m@singhealth.com.sg

Received Date: December 10, 2025

Accepted Date: February 03, 2026

Citation:

Loh MJM, Fan Y, Loy SL, Wong KY, Ku CW, Ee TX, et al. Autologous platelet-rich plasma to improve reproductive outcomes in women with diminished ovarian reserves: a prospective pilot study. J Clin Exp Reprod Med. 2026;3(1):1-9.


Copyright: © 2026 Loh MJM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are edited.

Abstract

Objective: To investigate if intraovarian autologous platelet-rich plasma (PRP) infusion improve ovarian reserve markers and fertility outcomes in women with diminished ovarian reserve (DOR). 
Methods: A single-arm, prospective intervention study was conducted between July 2023 and April 2024. Women aged 21–40 years with DOR and previous poor response to maximal ovarian stimulation during IVF were recruited. Anti-mullerian hormone (AMH) and antral follicle count (AFC) were measured on menstrual cycle days 2–3, followed by PRP injection on days 5–15. AMH and AFC were reassessed 2–3 months later, and ovarian stimulation commenced 3–6 months post PRP. Primary outcomes were changes in ovarian reserve markers and fertility outcomes. Secondary outcomes were clinical pregnancy and live birth rates.
Results: Thirteen women underwent PRP injection (median age: 38.0 years; median body mass index: 22.2 kg/m2). Median AMH and AFC showed a numerical increase post-PRP (0.17 to 0.26 ng/ml and 5.0 to 6.0 respectively), though these changes did not reach statistical significance (p=0.695 and p=0.509). Median number oocytes retrieved increased (1.8 to 3.0 (p=0.099)). Median number of mature oocytes retrieved increased significantly (2.0 to 3.0; p=0.019) and embryos created (1.0 to 2.0; p=0.025). Clinical pregnancy rate was 41.7% and live birth rate was 33.3%. No complications were reported during PRP infusion.
Conclusion: Intraovarian PRP is a safe treatment option which may improve reproductive outcomes in DOR women. Larger, well-controlled studies to establish clinical applicability are warranted.

Keywords

Platelet-rich plasma (PRP), Autologous PRP, Diminished ovarian reserves, Poor ovarian response, In vitro fertilization (IVF), Assisted reproductive technology (ART)

Recommended Articles

Neodymium:YAG laser posterior capsulotomy in the lateral decubitus position

Here we report a novel method of performing a Neodyminium:YAG (Nd:YAG) laser posterior capsulotomy in an adult patient, unable to tolerate the procedure awake with topical anaesthesia in the outpatient clinic setting. The procedure was performed by altering the chin rest and arms of the Nd:YAG laser machine so that the procedure could be undertaken in an anaesthetized patient in the operating theatre, in the lateral decubitus position, with the laser machine upright in its normal position.

Presbyopia correcting IOLs and the ocular surface disease… The good, the bad and the ugly

The last two decades were especially fruitful for the refractive surgeons and for the industry who have been showing tremendous development in both understanding and meeting patients’ desire for spectacle independence. Ever since the first trials from Dr. Kenneth Hoffer with his early 1980’s effort in producing a multifocal IOL to the latest achievements from different companies in putting trifocals and EDOF optics to the market.

How many mutations does it take to make a uveal melanoma?

Uveal melanoma (UM) is a rare cancer that affects the choroid and, less frequently, the ciliary body or the iris (for recent reviews see [1-3]). Despite a profound knowledge of the oncogenic mechanisms behind UM tumorigenesis and despite an accurate cytogenetic and molecular prognosis, only limited advances have been made in UM therapy.

MSICS is a Simple Solution for a Big Problem

Manual small-incision cataract surgery (MSICS) is a sutureless cataract surgery that has multiple advantages over traditional phacoemulsification and extracapsular cataract extraction (ECCE) procedures. SICS became the procedure of choice for international ophthalmology, where the microscopes and operating room can be more challenging, in addition to the more advanced pathology often seen.

Surgical smoke and SARS-CoV-2 transmission

The protection of health care workers from nosocomial infection is a paramount consideration in the current pandemic involving severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Not only is prevention of viral transmission the most effective means to lessen the public health impact of coronavirus disease 2019 (COVID-19), but also both quarantine and illness – that disproportionately affect health care workers – have devastating effects on the ability of hospitals to adequately care for increased patient loads.

Full Text
Cite
Download PDF
Author Information X